Afluria Quadrivalent (influenza vaccine) has been approved by the US Food and Drug Administration for use in the over fives, extending the marketable application from its current indication in the adult population.
Developed by influenza vaccine specialist Seqirus, a subsidiary of Australian biotech firm CSL Limited (ASX: CSL), Afluria Quadrivalent helps protect against two influenza A strain viruses and two B strain viruses.
First approved in the USA in August 2016, the vaccine is available for this year’s flu season.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze